阿富汗单价轮状病毒疫苗的有效性与影响:检测阴性病例对照分析
阿富汗2018年1月将单价轮状病毒疫苗(Rotarix)纳入国家免疫规划,本研究采用检测阴性病例对照设计评估疫苗有效性,并比较接种前后监测数据评估影响。两剂Rotarix对6-59月龄儿童轮状病毒住院的有效性为45%(95%CI 22-62),轮状病毒阳性率从接种前51%降至接种后39%,调整后降低39%。
要点
- 两剂Rotarix对6-59月龄儿童轮状病毒住院的有效性为45%(95%CI 22-62)。
- 轮状病毒阳性率从接种前51%降至接种后39%,调整后降低39%。
- 作者认为研究结果支持在阿富汗继续接种轮状病毒疫苗。
核心结论
- Rotarix在预防轮状病毒胃肠炎住院方面显示中等有效性,与其他低收入国家的研究结果一致。
- 作者认为这些发现支持在阿富汗继续接种轮状病毒疫苗。
研究设计与样本
- 采用嵌入主动哨点监测平台的检测阴性病例对照设计评估疫苗有效性。
- 纳入2018年1月1日及以后出生、有轮状病毒疫苗接种记录、2018年5月至2021年12月在四家哨点医院因急性胃肠炎住院的儿童。
- 使用非条件logistic回归模型估计完成全程接种相对于未接种轮状病毒疫苗剂次的疫苗有效性和95%CI。
- 比较两个哨点2013-15年(接种前)和2019-21年(接种后)监测数据计算疫苗影响。
主要发现
- 疫苗有效性分析纳入1172例病例和2173例对照。
- 3345例病例和对照中约2108例(63.0%)为男性,1237例(37.0%)为女性,2171例(65.0%)年龄为6-11月龄。
- 调整年龄、严重程度、入院年份和轮状病毒季节后,两剂Rotarix对6-59月龄儿童轮状病毒住院的有效性为45%(95%CI 22-62)。
- 轮状病毒阳性率从接种前51%降至接种后39%,5岁以下因急性胃肠炎住院儿童的轮状病毒阳性率调整后降低39%。
临床怎么用
- 作者认为这些发现支持在阿富汗继续接种轮状病毒疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Afghanistan introduced monovalent rotavirus vaccine (Rotarix) into its national immunisation schedule in January, 2018. While post-licensure studies have shown substantial declines in rotavirus gastroenteritis cases and deaths globally, there is little evidence of rotavirus vaccine effectiveness and impact from low-income countries in Asia. We aimed to evaluate the effectiveness of the Rotarix vaccine and the impact of Rotarix vaccine on rotavirus gastroenteritis hospitalisations (ie, hospital admissions) among children younger than 5 years in Afghanistan. METHODS: We used a test-negative case-control design embedded in an active sentinel surveillance platform to evaluate vaccine effectiveness. Children born on or after Jan 1, 2018, who had documentation of their rotavirus vaccination status and who were admitted for acute gastroenteritis at one of four sentinel hospitals from May, 2018 to December, 2021 were eligible to be included. We used an unconditional logistic regression model to estimate vaccine effectiveness and 95% CIs for a complete series of doses compared with no rotavirus vaccine doses among patients admitted with acute gastroenteritis. Vaccine effectiveness against hospitalisation was calculated as (1 - [odds of being vaccinated in cases] / [odds of being vaccinated in controls]) × 100%. We compared pre-vaccine (2013-15) and post-vaccine (2019-21) surveillance data from two sites to calculate vaccine impact. FINDINGS: The vaccine effectiveness analysis included 1172 cases and 2173 controls. Approximately 2108 (63·0%) of 3345 cases and controls were male, 1237 (37·0%) were female, and 2171 (65·0%) were aged 6-11 months. Two doses of Rotarix were 45% (95% CI 22-62) effective against rotavirus hospitalisation in children aged 6-59 months, adjusting for age, severity, admission year, and rotavirus season. Rotavirus positivity decreased from 51% pre-vaccine to 39% post-vaccine, resulting in a 39% adjusted reduction in rotavirus positivity among children younger than 5 years admitted with acute gastroenteritis. INTERPRETATION: Rotarix showed moderate effectiveness in preventing rotavirus gastroenteritis hospitalisations, consistent with findings in other low-income countries. These findings support the continued administration of the rotavirus vaccine in Afghanistan. FUNDING: Gavi, the Vaccine Alliance. TRANSLATION: For the Dari translation of the abstract see Supplementary Materials section.
引用
- Anwari P, Burnett E, Safi N, et al. Effectiveness and impact of monovalent rotavirus vaccination in Afghanistan: a test-negative case-control analysis. Lancet Glob Health. 2024. PMID: 39151986. doi:10.1016/S2214-109X(24)00237-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。